Rowland & Co. Investment Counsel ADV lifted its position in Eli Lilly and Company (NYSE:LLY) by 0.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,071 shares of the company’s stock after acquiring an additional 309 shares during the quarter. Eli Lilly and accounts for 1.6% of Rowland & Co. Investment Counsel ADV’s portfolio, making the stock its 23rd largest position. Rowland & Co. Investment Counsel ADV’s holdings in Eli Lilly and were worth $3,711,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Eli Lilly and by 7,093.5% during the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares in the last quarter. Dodge & Cox raised its holdings in shares of Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after purchasing an additional 5,964,955 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after purchasing an additional 2,714,505 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after purchasing an additional 2,181,701 shares in the last quarter. Hedge funds and other institutional investors own 76.61% of the company’s stock.
Shares of Eli Lilly and Company (LLY) opened at $84.03 on Friday. The firm has a market cap of $92,139.64, a P/E ratio of 20.46, a price-to-earnings-growth ratio of 1.85 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $65.66 and a 12-month high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is presently 98.58%.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the sale, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 772,003 shares of company stock worth $64,837,441. 0.20% of the stock is owned by insiders.
Several research firms have recently commented on LLY. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the company a “hold” rating in a report on Friday, October 6th. Leerink Swann boosted their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $84.23 to $88.00 in a report on Tuesday, October 10th. Finally, Goldman Sachs Group Inc restated a “buy” rating and issued a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $90.25.
WARNING: This article was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/11/25/rowland-co-investment-counsel-adv-has-3-71-million-stake-in-eli-lilly-and-company-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.